Objectives: Acute aortic dissection (AAD) is a common disease among the elderly. Although several risk factors of AAD have been reported, the molecular mechanism underlying AAD development remains to be elucidated. Recent findings based on lipid molecular analysis have made a major contribution to the understanding of the pathogenesis of cardiovascular diseases, and it is now recognized that metabolic abnormalities, especially serum dyslipidemia, correlate with AAD onset and aortic rupture. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted enzyme that promotes the degradation of surface low-density lipoprotein (LDL) receptors (LDLRs), preventing the removal of LDL-cholesterol from the blood. Therefore, a PCSK9 inhibitor is a promising therapeutic tool for treating cardiovascular diseases. In this study, the objective was to elucidate the role of PCSK9 in the pathogenesis of AAD.
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Objectives: Acute aortic dissection (AAD) is a common disease among the elderly. Although several risk factors of AAD have been reported, the molecular mechanism underlying AAD development remains to be elucidated. Recent findings based on lipid molecular analysis have made a major contribution to the understanding of the pathogenesis of cardiovascular diseases, and it is now recognized that metabolic abnormalities, especially serum dyslipidemia, correlate with AAD onset and aortic rupture. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted enzyme that promotes the degradation of surface low-density lipoprotein (LDL) receptors (LDLRs), preventing the removal of LDL-cholesterol from the blood. Therefore, a PCSK9 inhibitor is a promising therapeutic tool for treating cardiovascular diseases. In this study, the objective was to elucidate the role of PCSK9 in the pathogenesis of AAD.
Methods: We used fluorescence immunohistochemistry to assess PCSK9 expression in the aortic tissues resected from 10 AAD patients and in normal aortic tissues from five autopsy samples as well as in an experimental aortic dissection (AD) model based on spontaneously hyperlipidemic apolipoprotein E-deficient mice.
Results: Histologically, PCSK9 expression in aortic tissue was significantly higher in AAD than that in control patients, and a characteristic distribution pattern of PCSK9 was found in atherosclerotic plaques and the degenerated tunica media in AAD tissues, which was rarely observed in normal aortic tissues. Smooth muscle cells were positively stained for PCSK9, which was confirmed by costaining with the smooth muscle cell marker. Furthermore, PCSK9 expression appeared significantly stronger in comparison with the tissues not accompanied with medial arterial calcification. Finally, we analyzed the level of PCSK9 expression on aneurysm formation via aortic dissection using the mice aorta. The fluorescence intensity of PCSK9 expression in media of aortic dissection mice was elevated by approximately fourfold compared with that of control mice 28 days after the procedure, indicating that the animal model confirmed PCSK9 expression in AD tissues (Fig) .
Conclusions: Our findings suggest that PCSK9 expression in aortic tissues may promote AAD. This study adds to the growing body of evidence supporting the use of PCSK9 inhibitors for the management of AAD. Objectives: Diabetic patients suffer an increased risk of restenosis and late stent thrombosis after angioplasty, complications that are related to a defective re-endothelialization. Dipeptidyl peptidase-4 inhibitors have been suggested to exert direct effect on endothelial and smooth muscle cells (SMCs). Therefore, the objective was to study whether the dipeptidyl peptidase-4 inhibitor linagliptin could influence vascular repair and accelerate re-endothelialization after arterial injury in healthy and diabetic animals.
Methods: Diabetic Goto-Kakizaki and healthy Wistar rats were subjected to arterial injury and treated with linagliptin or vehicle. Vessel wall healing was monitored noninvasively using ultrasound imaging and upon sacrifice with Evans blue staining and immunohistochemistry. The effect of linagliptin on SMCs was also studied in vitro.
Results: We observed a delay in the healing response in the diabetic animals compared with the Wistar controls. Goto-Kakizaki rats had more pronounced intimal hyperplasia, which affected the lumen diameter. We found that linagliptin reduced the proliferation and dedifferentiation of SMCs in vitro and modulated the inflammatory response in the SMCs after arterial injury in vivo. However, these effects of linagliptin did not affect the neointima formation or the re-endothelialization under normal and diabetic conditions.
Conclusions: Although linagliptin did not influence vessel wall healing, it appears to possess a desirable antiproliferative influence on SMCs in vitro and an anti-inflammatory effect in vivo. These pharmacologic properties might carry a potential significance for favorable outcome after vascular interventions in diabetic patients.
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Decreased CD26 Triggers the Differentiation of Monocytes Into Macrophages in Abdominal Aortic Aneurysm
Hsin-Ying Lu, Chun-Che Shih. Taipei Veterans General Hospital Objectives: CD26 is a 110-kDa glycoprotein that is expressed on numerous cell types and has multiple biological functions, including immune regulation, signal transduction, and apoptosis. We aimed to evaluate the expression of CD26 on mononuclear cells and its potential role in abdominal aortic aneurysm (AAA) evolution.
Methods: The study recruited 20 AAA patients and 20 healthy controls. CD26 expression on mononuclear cells was measured using flow cytometry. In addition, phorbol 12-myristate 13-acetate (PMA)-induced THP-1 cells and angiotensin II-infused apolipoprotein EtmlUnc mice were used to explore the underlying mechanisms.
Results: A significant decline in CD26 expression of monocytes in patients with AAA was observed relative to the control (CTL) group (Fig 1) . In vitro study demonstrated that PMA-treated cells decreased CD26 expression. The inhibition of CD26 markedly promoted PMA-induced monocytic cells differentiation by increased p21 expression, which regulated by extracellular signal-regulated protein kinase 1/2 (ERK 1/2) activation (Fig 2, A) . Finally, the animal study was used to confirm the in vitro results that mice with large AAA (LAA) showed marked macrophage infiltration in the adventitia with a decreased expression of DPP-4 compared with mice with small AAA (SAA; Fig 2, B) .
Conclusions:
The decreased CD26 expression on monocytes associated with aneurysmal development that participated in the monocyte-macrophage differentiation via extracellular signal-regulated protein kinase 1/2-p21 axis signaling pathways. The AAA influent factor, CD26, may involve future therapeutic element.
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Objectives: Wound healing in chronic inflammatory diseases, such as diabetes, is impaired due to failed resolution of inflammation. Innate immune cells, particularly macrophages, play a significant role in the 
